Results 41 to 50 of about 66,449 (275)
Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma [PDF]
, 2018 In this study, our aim is to assess the role played by autophagy and its inhibition in the different PDAC cellular compartments, and its involvement in chemo-resistance using primary human pancreatic cancer-derived cells (PCC) and Cancer Associated ...
Bintz, Jennifer +6 more
core +1 more source
Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. The standard chemotherapeutic drug, gemcitabine, does not offer significant improvements for PDAC management due to the rapid acquisition of drug resistance by patients.
Bielli, Pamela +7 more
core +2 more sources
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. [PDF]
, 2016 Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic
Chen, Qiu-Dan +8 more
core +2 more sources
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters [PDF]
Cancers, 2021 Gemcitabine (GCB) resistance is a major issue in bladder cancer chemoresistance, but its underlying mechanism has not been determined. Epithelial-mesenchymal transition (EMT) has been shown to be comprehensively involved in GCB resistance in several other cancer types, but the direct connection between EMT and GCB remains unclear.
Ying-Si Wu +7 more
openaire +2 more sources
Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]
, 2003 Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core +1 more source
Oncology Letters, 2019 Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer is one of the most malignant tumor types to affect the digestive system. Gemcitabine chemotherapy is typically the first choice of treatment for advanced pancreatic cancer; however, chemoresistance is a major obstacle to successful treatment.
Yu, Yue +4 more
openaire +3 more sources
Gemcitabine and anthracyclines in platinum-resistant ovarian cancer
Annals of Oncology, 2006 Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment. Gemcitabine (G) and Anthracyclines are active in this setting and their combination has shown synergistic antiproliferative activity in vitro, due to different mechanisms of action and non-overlapping toxicities.In ...
E, Galligioni +3 more
openaire +2 more sources
Autophagy and urothelial carcinoma of the bladder: A review. [PDF]
, 2016 The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan +1 more
core +2 more sources
Bangladesh Journal of PharmacologyGemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu +5 more
doaj +1 more source